## Hepatitis A and B Combined Vaccine (HABV)

### Revision Date: January 23, 2017

Please consult the Product Monograph for further information about the vaccine.

<table>
<thead>
<tr>
<th><strong>TWINRIX® Junior &amp; TWINRIX®</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturer</strong></td>
</tr>
</tbody>
</table>
| **Licensed use** | TWINRIX® Junior – individuals one year up to and including 18 years of age  
TWINRIX® – Individuals 19 years of age and older |
| **Off-license use** | None |
| **Indications for use of provincially funded vaccine** | **Pre-exposure:**  
Individuals one year of age and older (who are eligible for both hepatitis A and hepatitis B vaccines) including those with:  
- Hemophilia A or B receiving plasma-derived replacement clotting factors.  
- Chronic liver disease, including individuals infected with hepatitis C.  
- Lifestyle risks of infections including people engaging in illicit drugs (injectable and non-injectable) and men having sex with men.  
**Notes:**  
- TWINRIX® Junior/TWINRIX® should not be used for individuals who require double-strength hepatitis B vaccine. See [Biological Products – Hepatitis B Vaccine](#).  
- Pre-immunization serology for anti-HAV (IgG) is recommended for some individuals. See [Biological Products - Hepatitis A Vaccine](#).  
**Post-exposure:**  
TWINRIX® and TWINRIX® Junior is not recommended for hepatitis A or hepatitis B post-exposure prophylaxis. |
| **Dose** | TWINRIX® Junior (one year up to and including 18 years of age)  
- 0.5 mL dose  
TWINRIX® (19 years of age and older)  
- 1.0 mL |
| **Route** | Intramuscular injection |
| **Schedule** |  
- Dose 1 – day 0  
- Dose 2 – one month after dose 1  
- Dose 3 – six months after dose 1 |
| **Contraindications** |  
- Known severe hypersensitivity to any component of TWINRIX®, TWINRIX® Junior/TWINRIX®.  
- Anaphylactic or other allergic reactions to a previous dose of vaccine containing hepatitis A or hepatitis B antigens. |
## Precautions

It is possible that individuals may be in the incubation period of a hepatitis A or hepatitis B infection at the time of immunization. It is not known whether TWINRIX® Junior/TWINRIX® will prevent hepatitis A and hepatitis B in such cases.¹

## Possible reactions following immunization

### TWINRIX® Junior

**Local reactions:**
- Pain and redness at the injection site.¹

**Systemic reactions:**
- Headache, fatigue, appetite lost, irritability, drowsiness, malaise, fever, gastrointestinal symptoms, rash, urticaria, lymphadenopathy and dizziness.¹
- Paraesthesia, hypoesthesia, hypotension, pruritus, myalgia, arthralgia and chills were observed in clinical trials with TWINRIX®.¹

### TWINRIX®

**Local reactions:**
- Pain, redness and swelling at the injection site.¹

**Systemic reactions:**
- Headache, decreased appetite, malaise, fever, gastrointestinal symptoms, rash, urticaria, lymphadenopathy, dizziness, paraesthesia, hypoesthesia, hypotension, pruritus, myalgia, arthralgia and chills.¹
- The following adverse reactions have been reported from post-marketing surveillance with either TWINRIX® or GlaxoSmithKline monovalent hepatitis A or B vaccines include: meningitis; thrombocytopenia; anaphylaxis; allergic reactions; nervous system disorders e.g., encephalopathy, encephalitis, neuritis, neuropathy, paralysis, convulsions; vasculitis; angioneurotic edema; lichen planus; erythema multiforme; arthritis; muscular weakness; abnormal liver function tests and immediate injection site pain, stinging and burning sensation.¹

**Notes:**
- No evidence of a causal association following hepatitis B vaccine has been demonstrated in a number of studies for the listed chronic illnesses: chronic fatigue syndrome, multiple sclerosis, Guillain-Barré syndrome (GBS) or rheumatoid arthritis.²
- There is no increase in adverse events when the combined vaccine is compared with the monovalent vaccines administered separately.²

Refer to: *Adverse Events Following Immunization (AEFI), Policy for Alberta Immunization Providers.*³

### Pregnancy

TWINRIX® should be administered to pregnant women who meet the indications for use of provincially funded vaccine.
- The safety of TWINRIX® has not been studied in clinical trials. However, because the vaccine is prepared from inactivated viruses, the theoretical risk to the developing fetus is expected to be low.²

### Lactation

TWINRIX® should be administered to breastfeeding mothers who meet the indications for use of provincially funded vaccine.
References

